C

China Meheco Group Co Ltd
SSE:600056

Watchlist Manager
China Meheco Group Co Ltd
SSE:600056
Watchlist
Price: 10.4 CNY 1.17%
Market Cap: ¥15.6B

China Meheco Group Co Ltd
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

China Meheco Group Co Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
C
China Meheco Group Co Ltd
SSE:600056
Interest Income Expense
-¥26m
CAGR 3-Years
45%
CAGR 5-Years
34%
CAGR 10-Years
8%
COSCO SHIPPING Development Co Ltd
SSE:601866
Interest Income Expense
-¥1.6B
CAGR 3-Years
-49%
CAGR 5-Years
-66%
CAGR 10-Years
N/A
Sichuan New Energy Power Co Ltd
SZSE:000155
Interest Income Expense
-¥204.5m
CAGR 3-Years
11%
CAGR 5-Years
-12%
CAGR 10-Years
-10%
C
CITIC Metal Co Ltd
SSE:601061
Interest Income Expense
¥1.6B
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
China National Uranium Co Ltd
SZSE:001280
Interest Income Expense
¥124.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
JINGDONG Industrials Inc
HKEX:7618
Interest Income Expense
¥61.5m
CAGR 3-Years
108%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

China Meheco Group Co Ltd
Glance View

China Meheco Group Co., Ltd., established in 1984, stands as a prominent player in the Chinese pharmaceutical and healthcare sector. As the company evolved over the decades, it navigated the complex Chinese market by strategically positioning itself across the entire pharmaceutical value chain. This involved investing heavily in research and development, securing partnerships with both domestic and international pharmaceutical companies, and streamlining its distribution network to enhance efficiency. Such endeavors have enabled China Meheco to develop and distribute a wide range of medical products, including active pharmaceutical ingredients, finished drugs, medical devices, and traditional Chinese medicines. The company leverages its robust R&D capabilities to continually bring innovative products to market, which has been a significant source of its revenue. China Meheco's business model thrives on its expansive distribution network and strategic collaborations. By aligning with global pharmaceutical giants, the company not only gains access to cutting-edge technologies and advanced formulations but also expands its market reach beyond China. This dual strategy of innovation and partnership ensures a steady flow of products that cater to diverse healthcare needs. Furthermore, China Meheco capitalizes on its local expertise and deep understanding of regulatory frameworks, allowing it to maneuver efficiently within China's complex healthcare landscape. This approach underpins its ability to capture substantial market share in a competitive industry, driving profitability and positioning the company as a key player in the global pharmaceutical arena.

Intrinsic Value
15.12 CNY
Undervaluation 31%
Intrinsic Value
Price ¥10.4
C

See Also

What is China Meheco Group Co Ltd's Interest Income Expense?
Interest Income Expense
-26m CNY

Based on the financial report for Sep 30, 2025, China Meheco Group Co Ltd's Interest Income Expense amounts to -26m CNY.

What is China Meheco Group Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
8%

Over the last year, the Interest Income Expense growth was 88%. The average annual Interest Income Expense growth rates for China Meheco Group Co Ltd have been 45% over the past three years , 34% over the past five years , and 8% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett